From: DNA methylation for cervical cancer screening: a training set in China
 | OR (95% CI) of positive methylationa | p | OR (95% CI) of positive hrHPVa | p | OR (95% CI) of positive methylation and hrHPVa | p |
---|---|---|---|---|---|---|
Inflammation (n = 78) | Reference | – | Reference | – | Reference | – |
CIN1 (n = 40) | 0.461 (0.093–2.279) | 0.342 | 1.269 (0.519–3.106) | 0.602 | 0.374 (0.042–3.318) | 0.377 |
CIN2 (n = 29) | 2.283 (0.717–7.271) | 0.163 | 1.158 (0.432–3.106) | 0.771 | 3.042 (0.810–11.416) | 0.099 |
CIN3 (n = 91) | 21.875 (9.244–51.764) | < 0.001 | 4.421 (1.763–11.804) | 0.002 | 29.687 (10.856–81.178) | < 0.001 |
SCC (n = 52) | 446.250 (54.106–3680.553) | < 0.001 | 6.018 (1.692–21.396) | 0.006 | 238.467 (54.479–1043.821) | < 0.001 |
Endocervical ADC (n = 11) | 87.500 (9.872–775.520) | < 0.001 | 1.658 (0.331–8.309) | 0.539 | 65.700 (11.079–389.600) | < 0.001 |
Inflammation or CIN1 (n = 118) | Reference | – | Reference | – | Reference | – |
CIN2+ (n = 183) | 27.953 (13.552–57.656) | < 0.001 | 2.943 (1.567–5.527) | 0.001 | 39.232 (16.308–94.381) | < 0.001 |